KLDO — Kaleido Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$16.78m
- $1.10m
U.S. STOCKS ON THE MOVE-Alaska Air, Acacia Communications, Gilead Sciences Inc, Apache Corp
U.S. STOCKS ON THE MOVE-China tech giants, NantKwest, Chembio Diagnostics, Delta Air Lines
Kaleido Biosciences: Rises on positive data from COVID-19 treatment trial
Brief: Kaleido Biosciences Announces Completion Of Enrollment Of 350 Subjects In Controlled Study Of KB109 In Treatment Of Mild-To-Moderate COVID-19
Brief: Kaleido Biosciences Reports Q3 2020 Financial Results
Brief: Kaleido Biosciences Inc - Changed Michael Bonney’S Role From Executive Chair Of The Board To Chair Of The Board, Effective As Of October 13, 2020
Brief: Kaleido Biosciences Provides Update On KB109 Clinical Data Timeline
Brief: Kaleido Biosciences Appoints Daniel Menichella As President And Chief Executive Officer
Kaleido: Rises on starting inflammatory bowel disease therapy study
Brief: Kaleido Biosciences Says First Patient Dosed In Clinical Study Of Microbiome Metabolic Therapy Kb295 In Patients With Mild-To-Moderate Ulcerative Colitis
Brief: Kaleido Biosciences Presents Data For Microbiome Metabolic Therapy KB174 For Hepatic Encephalopathy
Brief: Kaleido Biosciences Reports Second Quarter 2020 Financial Results And Provides Corporate Update
Brief: Kaleido Biosciences Files For Mixed Shelf Of Upto $150 Mln - SEC Filing
Kaleido Biosciences up on launching second study of potential COVID-19 drug
Brief: Kaleido Initiates Controlled Clinical Study Of Microbiome Metabolic Therapy In Outpatients With Mild-To-Moderate COVID-19
Brief: Kaleido Biosciences & Units Entered Into A 2nd Amendment To Loan And Security Agreement
Brief: Kaleido Biosciences Says Alison Lawton To Step Down As Chief Executive Officer
Kaleido Biosciences down as stock offering priced at discount
Brief: Kaleido Biosciences Announces Pricing Of Public Offering Of Common Stock